26250 Federal Register / Vol. 74, No. 103 / Monday, June 1, 2009 / Notices 

Colesville Rd., Silver Spring, MD. The 

hotel telephone number is 301–589– 

5200. 

Contact Person: Janie Kim, Center for 

Drug Evaluation and Research (HFD– 

21), Food and Drug Administration, 

5600 Fishers Lane (for express delivery, 

5630 Fishers Lane, rm. 1093) Rockville, 

MD 20857, 301–827–7001, FAX: 301– 

827–6776, email: 

Janie.kim@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572) in the 

Washington, DC area), code 

3014512539. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: The committee will discuss 

bioequivalence recommendations for 

oral vancomycin hydrochloride capsule 

drug products. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ohrms/ 

dockets/ac/acmenu.htm, click on the 

year 2009 and scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before July 21, 2009. Oral 

presentations from the public will be 

scheduled between approximately 1 

p.m. and 2 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before July 13, 2009. Time allotted for 

each presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by July 14, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Janie Kim at 

least 7 days in advance of the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/oc/advisory/ 

default.htm for procedures on public 

conduct during advisory committee 

meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: May 20, 2009. 

Randall W. Lutter, 

Deputy Commissioner for Policy. 

[FR Doc. E9–12627 Filed 5–29–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Dermatologic and Ophthalmic Drugs 

Advisory Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Dermatologic 

and Ophthalmic Drugs Advisory 

Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on June 26, 2009, from 8 a.m. to 5 

p.m. 

Location: Hilton Washington DC/ 

Silver Spring, Maryland Ballrooms, 

8727 Colesville Rd., Silver Spring, MD. 

The hotel phone number is 301–589– 

5200. 

Contact Person: Paul Tran, Center for 

Drug Evaluation and Research (HFD– 

21), Food and Drug Administration, 

5600 Fishers Lane (for express delivery, 

5630 Fishers Lane, Rm. 1093) Rockville, 

MD 20857, 301–827–7001, FAX: 301– 

827–6778, e-mail: 

paul.tran@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512534. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: The committee will discuss 

new drug applications (NDAs) 22–288, 

BEPREVE (bepotastine besilate) 

ophthalmic solution, 1.5%, ISTA 

Pharmaceuticals, Inc., proposed for the 

treatment of ocular itching associated 

with allergic conjunctivitis, and NDA 

22–358, sodium hyaluronate ophthalmic 

solution, 0.18%, River Plate 

Biotechnology, Inc., proposed for the 

treatment of the signs and symptoms of 

dry eye disease. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ohrms/ 

dockets/ac/acmenu.htm, click on the 

year 2009 and scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before June 17, 2009. Oral 

presentations from the public will be 

scheduled between approximately 9:30 

a.m. to 10 a.m., and 1:30 p.m. to 2 p.m. 

Those desiring to make formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

Federal Register / Vol. 74, No. 103 / Monday, June 1, 2009 / Notices 26251 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before June 11, 

2009. Time allotted for each 

presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by June 12, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact John 

Lauttman at 301–827–7001, at least 7 

days in advance of the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/oc/advisory/ 

default.htm for procedures on public 

conduct during advisory committee 

meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: May 20, 2009. 

Randall W. Lutter, 

Deputy Commissioner for Policy. 

[FR Doc. E9–12625 Filed 5–29–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Privacy Act of 1974, as Amended; 

Computer Matching Program 

AGENCY: Administration for Children 

and Families (ACF). 

ACTION: Notice of a computer matching 

program. 

SUMMARY: In compliance with the 

Privacy Act of 1974, as amended by 

Public Law 100–503, the Computer 

Matching and Privacy Protection Act of 

1988, ACF is publishing a notice of a 

computer matching program. The 

purpose of this computer match is to 

identify specific individuals who are 

receiving benefits from the Department 

of Veterans Affairs (VA) and also 

receiving payments pursuant to various 

benefit programs administered by both 

the Department of Health and Human 

Services (HHS) and the Department of 

Agriculture. ACF will facilitate this 

program on behalf of the State Public 

Assistance Agencies (SPAAs) that 

participate in the Public Assistance 

Reporting Information System (PARIS) 

for verification of continued eligibility 

for public assistance. The match will 

utilize VA and SPAA records. 

DATES: ACF will file a report of the 

subject matching program with the 

Committee on Homeland Security and 

Governmental Affairs of the Senate and 

the Committee on Oversight and 

Government Reform of the House of 

Representatives and the Office of 

Information and Regulatory Affairs 

within the Office of Management and 

Budget (OMB). The dates for the 

matching program will be effective as 

indicated below. 

ADDRESSES: Interested parties may 

comment on this notice by writing to 

the Director, Office of Financial 

Services, Office of Administration, 370 

L’Enfant Promenade, SW., Washington, 

DC 20047. All comments received will 

be available for public inspection at this 

address. 

FOR FURTHER INFORMATION CONTACT: 

Director, Office of Financial Services, 

Office of Administration, 370 L’Enfant 

Promenade, SW., Washington, DC 

20047. Telephone: (202) 401–7237. 

SUPPLEMENTARY INFORMATION: Public 

Law 100–503, the Computer Matching 

and Privacy Protection Act of 1988, 

amended the Privacy Act (5 U.S.C. 552a) 

by adding certain protections for 

individuals applying for and receiving 

Federal benefits. The law regulates the 

use of computer matching by Federal 

agencies when records in a system of 

records are matched with other Federal, 

State, and local government records. 

Federal agencies that provide or 

receive records in computer matching 

programs must: 

1. Negotiate written agreements with 

source agencies; 

2. Provide notification to applicants 

and beneficiaries that their records are 

subject to matching; 

3. Verify match findings before 

reducing, suspending, or terminating an 

individual’s benefits or payments; 

4. Furnish detailed reports to 

Congress and OMB; and 

5. Establish a Data Integrity Board that 

must approve matching agreements. 

This computer matching program 

meets the requirements of Public Law 

100–503. 

Dated: 05/27/2009. 

Curtis L. Coy, 

Deputy Assistant Secretary for 

Administration, ACF. 

Notice of Computer Matching Program 

A. PARTICIPATING AGENCIES

VA and SPAAs. 

B. PURPOSE OF THE MATCH

To identify specific individuals who 

are receiving benefits from the VA and 

also receiving payments pursuant to 

HHS and Department of Agriculture 

benefit programs, and to verify their 

continued eligibility for such benefits. 

SPAAs will contact affected individuals 

and seek to verify the information 

resulting from the match before 

initiating any adverse actions based on 

the match results. 

C. AUTHORITY FOR CONDUCTING THE MATCH

The authority for conducting the 

matching program is contained in 

section 402(a)(6) of the Social Security 

Act [42 U.S.C. 602(a)(6)]. 

D. RECORDS TO BE MATCHED

VA will disclose records from its 

Privacy Act system of records titled, 

‘‘Compensation, Pension, Education, 

and Rehabilitation Records—VA 

(58VA21/22/28)’’ last published at 74 

FR 14865 on April 1, 2009. VA’s 

disclosure of information for use in this 

computer match is listed as a routine 

use in this system of records. 

VA, as the source agency, will prepare 

electronic files containing the names 

and other personal identifying data of 

eligible veterans receiving benefits. 

These records are matched 

electronically against SPAA files 

consisting of data regarding monthly 

Medicaid, Temporary Assistance for 

Needy Families, general assistance, and 

Food Stamp beneficiaries. 

1. The electronic files provided by the 

SPAAs will contain client names and 

Social Security Numbers (SSNs). 

2. The resulting output returned to the 

SPAAs will contain personal identifiers, 

including names, SSNs, employers, 

current work or home addresses, etc. 

E. INCLUSIVE DATES OF THE MATCHING PROGRAM

The effective date of the matching 

agreement and date when matching may 

actually begin shall be at the expiration 

of the 40-day review period for OMB 

and Congress, or 30 days after 

publication of the matching notice in 

the Federal Register, whichever date is 

later. The matching program will be in 

effect for 18 months from the effective 

date, with an option to renew for 12 

additional months, unless one of the 

parties to the agreement advises the